288 results about "Antihistamine" patented technology

A pharmaceutical dosage form comprising a first drug and a second drug, both of which are selected from decongestants, antitussives, expectorants, analgesics and antihistamines. The dosage form provides a plasma concentration within a therapeutic range of the second drug over a period which is coextensive with at least about 70% of a period over which the dosage form provides a plasma concentration within a therapeutic range of the first drug. This Abstract is neither intended to define the invention disclosed in this specification nor intended to limit the scope of the invention in any way.

Compositions comprising a nanoparticulate corticosteroid and an antihistamine are described. The compositions are useful in the prophylaxis and chronic treatment of asthma in adults and pediatric patients and for the relief of allergic conjunctivitis, symptoms of seasonal allergic rhinitis in adults and pediatric patients. Combining an antihistamine with a nanoparticulate corticosteroid in a single formulation results in improved efficacy.

Methods to prevent or reduce inflammation secondary to administration of a lipid-nucleic acid complex in a subject, that include administering to the subject a non-steroidal anti-inflammatory agent, a salicylate, an anti-rheumatic agent, an antihistamine, or an immunsuppressive agent with the lipid-nucleic acid complex are disclosed. Also disclosed are methods of screening for inhibitors of the inflammatory response associated with administration of a lipid-nucleic acid complex to a subject, including providing a candidate substance suspected of preventing or inhibiting the inflammation associated with administration of a lipid-nucleic acid complex to the subject. Also disclosed are compositions that include a lipid, a nucleic acid, and a non-steroidal anti-inflammatory agent, a salicylate, an anti-rheumatic agent, an antihistamine, or an immunosuppressive agent.

The present invention relates to a method of enhancing the bioavailability of a piperidinoalkanol antihistamine in a patient which comprises co-administering to said patient an effective antihistaminic amount of said piperidinoalkanol and an effective p-glycoprotein inhibiting amount of a p-glycoprotein inhibitor.

This invention further relates to a method for preventing or treating diseases or conditions of the oral cavity, throat or nose of warm-blooded animals including humans. More particularly, the invention pertains to a composition and method for spraying essential oils to the oral cavity, throat or nasal mucosa as cyclodextrin inclusion complexes. The spray composition includes a cyclodextrin in an amount of from about 0.1% w / v to about 20% w / v; at least one essential oil in an amount of from about 0.001% w / v to about 5.0% w / v; an effective amount of an antimicrobial preservative composition; and water. The composition may further comprise an alcohol co-solvent, a thickening agent, a sweetener, an antitussive, an anticholinergic, a decongestant, an antihistamine, an astringent, an anti-inflammatory steroid composition, a vitamin, a respiratory stimulant, a mucolytic agent, a bronchodilator, a beta-antagonist, an antidiarrheal agent, or combinations thereof.

A mixed-release tablet or capsule formulation including vehicles for the delivery of a plurality of drugs in various combinations of immediate release, extended release, and / or delayed release modes over a predetermined time period have been developed, which provide for controlled release not just of the drugs, but controlled release that is designed to create more effective coordination between the drugs being delivered. The drugs can be any medically and / or physiologically appropriate combination of drugs and active ingredients, preferably decongestant drugs, antihistamines, expectorants, antitussives, cough suppressants, and drying agents.

The present invention relates to liquid sustained release suspension dosage forms. In particular, the invention encompasses sustained release compositions comprising a dispersed phase, which contains an ion-exchange matrix drug complex, a diffusion controlling membrane coating and a dispersion medium comprising an excipient capable of impeding water activity such that drug dissolution is inhibited prior to administration. Further, the invention provides for compositions wherein several active ingredients associate in a single bead in the dispersed phase, such that the abuse potential of such active ingredients is reduced. The invention also encompasses sustained release formulations of combination drugs comprising an extended release phase and an immediate release phase. The formulations of the invention may be used to treat a variety of conditions and symptoms, including those that require administration of several drugs, such as cold and allergy symptoms. In one of the embodiments, the sustained release composition combines an antihistamine, an antitussive and a decongestant. The invention further provides for methods of making and using such formulations.

Hypodermic syringes with multiple needles are used to practice a method of calming psychiatric patients. In accordance with one embodiment of the invention generally used to calm violent adult patients, the syringe has a first barrel containing an antipsychotic, a second barrel containing a sedating antihistamine and a third barrel containing an antianxiety sedative. Each barrel also has a separate projecting needle and contains a piston. A common operator, preferably in the form of a plunger simultaneously pushes all of the pistons so that the patient receives three injections simultaneously. For children, a second embodiment of the syringe includes two barrels instead of three, each barrel containing a separate medication. In each embodiment the syringe is packaged in a manually openable plastic envelope with a safety cap over the needles.

Compositions comprising both a sedative and a non-sedative antihistamine are disclosed as well as methods of inhibiting the release of histamines by administration of the compositions to a mammalian subject.

Disclosed are methods of treating allergic conjunctivitis and allergic rhinitis in a subject that involve topically administering to the subject a composition comprising a pharmaceutically effective amount of an H1 antagonist and an anti-TNFα compound.

The invention provides a topical pharmaceutical composition for application to the nasal or ocular mucosa which comprises (1) a pharmaceutical excipient suitable for topical administration, (2) an antihistamine drug and (3) a mast cell stabilizer, a non-steroidal anti-inflammatory drug, a phosphodiesterase inhibitor, an anti-IgE agent, heparin, a topical steroid or a leukotriene blocker.

Compositions, methods and kits are provided for the treatment of migraines. The compositions, methods and kits include an effective dose of trimethobenzamide and an ethanolamine antihistamine that, when administered to an individual suffering from migraine headaches, will alleviate symptoms associated with the migraine headaches. Compositions, methods, and kits for the treatment of migraines include pharmaceutical compositions of trimethobenzamide and diphenhydramine.

The invention discloses an itching-relieving body wash and a preparation method thereof. The itching-relieving body wash comprises the raw materials of, by mass, 1.0-20.0% of an amphoteric surfactant, 6.0-20.0% of an anionic surfactant, 0.5-8.0% of a non-ionic surfactant, 0.1-8.0% of a polyol humectant, 0.5-2.0% of a traditional Chinese medicine extract, 0.1-2.0% of a moisture, 0.01-2.0% of phytosterol, 0.01-0.5% of a chelating agent, 0-2.0% of a pearlescent agent, 0-2.0% of a viscosity adjusting agent, 0-0.5% of a conditioning agent, 0-0.5% of a foam stabilizing agent, 0-0.5% of an essence, 0-0.2% of a pH adjusting agent, 0-0.8% of a preservative, and balance of deionized water. The traditional Chinese medicine extract comprises a mixture of a purslane extract and a common cnidium fruit extract. The itching-relieving body wash has excellent antihistamine, antibacterial, bacteria-inhibiting, anti-inflammatory, and anti-allergic effects.

There is provided homogeneous pharmaceutical compositions for the treatment of, for example, rhinitis, asthma and / or chronic obstructive pulmonary disease comprising a corticosteroid and an antihistamine, a polar lipid liposome and a pharmaceutical-acceptable aqueous carrier.

The present invention relates to a novel combination of a soft steroid, in particular loteprednol, and at least one antihistamine, such as, for example, azelastine and / or levocabastine, for simultaneous, sequential or separate administration in the local treatment of allergies and airway disorders, for example of allergic rhinitis (rhinoconjunctivitis).

A solid pharmaceutical dosage unit for alleviating the symptoms of rhinorrhea. The dosage unit comprises an anticholinergic agent and an antihistamine and, optionally, a decongestant and, when placed in a basket in 500 ml of 0.01 N HCl of 37° C. which is stirred at 100 rpm, releases at least about 75% of the at least one anticholinergic agent within 45 minutes and releases the at least one antihistamine at a rate of from about 20% to about 60% after 2 hours, from about 45% to about 80% after 4 hours and at least about 75% after 8 hours. This Abstract is not intended to define the invention disclosed in the specification, nor intended to limit the scope of the invention in any way.

The present invention relates to an anti-allergic pharmaceutical composition containing at least two active agents chosen from among: (i) one allergen, (ii) one antihistamine compound, and (iii) one inhibitor of histamine synthesis. The active agents are associated in the composition with a pharmaceutically acceptable vehicle.

The invention discloses an alcohol dehydrogenase, a gene thereof, a recombinant expression vector and a recombinant expression transformant respectively containing the gene, a recombinase of the alcohol dehydrogenase, and an application of the alcohol dehydrogenase in asymmetric reduction synthesis of chiral diaryl secondary alcohol as a catalyst, and belongs to the technical field of bioengineering. The alcohol dehydrogenase is from Kluyveromyces sp. CCTCCM2011385, has a carbonyl group reduction function, and also has a hydroxy group oxidation function. Extra addition of glucose dehydrogenase and other enzymes used for cofactor circulation is not needed when the alcohol dehydrogenase is used in the reduction of diaryl ketone into the chiral diaryl secondary alcohol as a biocatalyst, and the alcohol dehydrogenase has the advantages of high catalysis efficiency, mild reaction conditions, easy product recovery and low cost, so the alcohol dehydrogenase has very good application and exploitation prospect in the production of antihistamine medicines.

Kits providing a combination of one or more pharmaceutical information comprising one or more agent(s) for the treatment or alleviation of symptoms commonly associated with a cold and an immunonutritional composition comprising immunonutritional agent and methods of using these kits are described . The kits provide both the pharmaceutical agent(s) and the immunonutritional agent in a convenient form for administration. The kit typically includes instruction for coordinating the administration of the pharmaceutical formulation with the administration of the immunonutritional composition. The preferred immunonutritional agents are compounds that contain a pharmaceutically acceptable form of zinc, such as zinc acetate, zinc gluconate, zinc gluconate glycine, and zinc sulfate. Preferably the kit contains multiple dosage forms containing the immunonutritional composition. In the most preferred embodiment, the immunonutritional composition is in the form of a lozenge. Suitable pharmaceutical agents include but are not limited to antihistamines, decongestants, anticholinergies, antitussives, analgestics, mucolytics, expectorants, and combinations thereof. The pharmaceutical formulations may be in any suitable dosage form, including forms which provide controlled release of the pharmaceutical agent, including immediate, sustained, modified, delayed or pulsed release pharmacokinetic mechanism or a combination thereof. The combined treatment requires administration of both the pharmaceutical formulation(s) for the treatment of symptoms commonly associated with a cold and the administration of the immunonutritional composition, which supplies nutritional support for the patient's innate immune response to the presence of infectious organisms.

Solid tablets or gel capsules comprising acetaminophen and an agent that promotes glutathione production that mitigates adverse hepatic effects of acetaminophen. The glutathione production promoter is preferably n-acetylcysteine or other mercapto-2-amino alkyl carboxylic acid having glutathione production promoting properties. A preferred composition comprises acetaminophen (200 mg to 750 mg) and N-acetylcysteine (200 mg to 600 mg). Alternatively and / or in addition to N-acetylcysteine the composition can contain at least one of methionine and cysteine. Preferred compositions can contain at least one of an opiate (or synthetic equivalent), an antihistamine, an antiemetic, and a sedative. Physical encapsulation of the ingredients optionally with or in place of a fragrance is used to make the composition more acceptable to patients by mitigating noxious properties of the glutathione production promoter. Preferably, the compositions are prepared for patient self administration in tablet or gel capsule form wherein the patients can take the medication without the need for close oversight of a medical caregiver.

The present invention provides a dual release solid dosage form containing a first composition that releases a neuraminidase inhibitor, such as oseltamivir, zanamivir, or peramivir, in a controlled manner and a second composition that releases an H1 antagonist in a rapid and / or immediate manner. A wide range of H1 antagonist antihistamines, especially fexofenadine and loratadine, can be used in this device. Particular embodiments of the invention provide osmotic devices having predetermined release profiles. The device is useful for the treatment of respiratory congestion and other viral infection associated symptoms.

It has been found that certain antihistamines can mediate the delayed dermatitis and in particular that caused by poison ivy and poison sumac or poison oak. Especially useful are antihistamines having a high degree of intrinsic activity as shown by their low oral dosage as antihistamine (0.1-10, suitably 1-2 mg), which can be topically administered at a sufficiently high active concentration to be effective in the treatment of allergic reactions. Compositions and methods of utilizing such compositions for these purposes are disclosed.

A topical pharmaceutical preparation suitable for use as an antihistamine or anti-nausea drug comprises an emu oil gel base and a therapeutic amount of promethazine.HCl. The preparation may further comprise an antioxidant. The preparation is preferably packaged as a single unit dose. A method for preparing the topical pharmaceutical preparation comprises the steps of combining a clear gel with an emu oil mixture and adding a therapeutic amount of promethazine.HCl solution.

The present invention provides pharmaceutical compositions including a sedating antihistamine and a stimulant, and methods of use thereof. The stimulant reduces the sedation caused by the antihistamine, thereby allowing potent, but sedating, antihistamines to be used effectively.

A composite medicine in which desloratadine is stabilized features that after desloratadine is mixed with medicinal auxiliaries, an antioxidizing agent is added to the mixture.